Processa details Vidya deal progress and new leadership in stockholder letter
Processa Pharmaceuticals issued a November 5, 2026 letter to stockholders outlining its I&I pipeline strategy, financing runway, and executive additions following the Vidya Therapeutics acquisition.
Processa Pharmaceuticals sent a letter to stockholders dated November 5, 2026, filed with the SEC as an exhibit to a Form 8-K. The company issued the letter to stockholders on November 5, 2026.1
The letter recaps the July transaction, in which Processa acquired Vidya Therapeutics and completed a concurrent private placement financing of approximately $200 million supported by leading institutional healthcare investors.1 That deal established a new strategic direction for the company focused on advancing differentiated therapeutic programs for immunological and inflammatory diseases, led by VT-7208, Vidya's lead investigational product candidate.1
On funding, Processa said the July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, supporting the previously disclosed Phase 2 proof-of-concept plan across food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.1
The company also described a second pipeline asset: an oral macrocyclic peptide-based neonatal Fc receptor (FcRn) antagonist program being advanced under a research collaboration and exclusive option agreement with Generian Pharmaceuticals.1
Leadership additions were announced as well. Dr. Sheila Gujrathi has been appointed Executive Chair of the Processa Board, and the company is adding four biotechnology leaders: Gregory J. Flesher in the chief operating officer role, Craig Coburn, Ph.D., leading research as an executive vice president, Ashley Hall, J.D., as an executive vice president overseeing development, and Michael P. Cruse as an executive vice president handling business operations.1
On capitalization, Processa noted 2.8 million common shares currently outstanding, with Series A preferred stock convertible to approximately 306.5 million common shares, for a total as-converted share count of about 309.3 million1, subject to stockholder approval. The company said definitive proxy materials for the first special meeting were filed on October 22, 2026, with mailing underway1, while materials for a second meeting remain pending.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.